Amgen (NASDAQ:AMGN) Target Lowered by Morgan Stanley to $235.00

Amgen stock has undergone multiple analysts rating changes in the recent past.  stock Target Lowered by Morgan Stanley on 10/12/2021. In a note to investors, the firm issued a new target price of $235.00. The analysts previously had $251.00 target price. Morgan Stanley’s price target would indicate a potential upside of 13.69% from the stock’s previous close.

Shares of traded on monday, reaching $204.73. 327615 shares of the stock traded hands, compared to its average volume of 2573332. On monday, Shares of closed at $204.73. The firm’s 50 day moving average is $220.40 and its 200 day moving average is $236.85.  has a 12 month low of $204.50 and a 12 month high of $276.69. While on yearly highs and lows, today has traded high as $207.56 and has touched $204.50 on the downward trend.

Earnings and What to expect: 

Amgen last posted its quarterly earnings data on August 2nd, 2021. The medical research company reported $4.38 EPS for the quarter, beating analysts’ consensus estimates of $4.09 by $0.29. The company earned $6.53 billion during the quarter, compared to analysts’ expectations of $6.43 billion. Amgen has generated $16.60 earnings per share over the last year ($9.83 diluted earnings per share) and currently has a price-to-earnings ratio of 21.0. Earnings for Amgen are expected to grow by 9.81% in the coming year, from $16.41 to $18.02 per share. Amgen has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, October 27th, 2021 based off prior year’s report dates.

Earnings for Amgen are expected to grow by 9.81% in the coming year, from $16.41 to $18.02 per share. The P/E ratio of Amgen is 21.03, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.29. The P/E ratio of Amgen is 21.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.41. Amgen has a PEG Ratio of 1.55. PEG Ratios above 1 indicate that a company could be overvalued. Amgen has a P/B Ratio of 12.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

(NASDAQ:AMGN) Moving Average Technical Analysis

5 day Moving Average is $$208.28 And 5 day price change is -$5.22 (-2.46%)  with average volume for 5 day average is 2,118,490. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $212.96 and 20 day price change is -$9.40 (-4.35%) and average 20 day moving volume is 2,538,228. 50 day moving average is $220.40  and 50 day price change is -$33.15 ( -13.82%)  and with average volume for 50 days is : 2,558,279. 200 day moving average is $236.85  and 200 day price change is -$16.29 (-7.31%)  and with average volume for 200 days is : 2,564,513.

Other owners latest trading in Amgen :

  • On 10/12/2021 shares held by American National Bank were 33,737 which equates to market value of $7.17M and appx 1.60% owners of Amgen
  • On 10/12/2021 shares held by First Hawaiian Bank were 10,986 which equates to market value of $2.34M and appx 0.10% owners of Amgen
  • On 10/8/2021 shares held by HBW Advisory Services LLC were 977 which equates to market value of $0.21M and appx 0.10% owners of Amgen
  • In total Institutional ownership equates to Institutional Ownership Percentage: 74.73% for Amgen

See More Analyst Rating at: RATING